6-ethynyl-4,4-dimethyl-2,3-dihydrothiochromene

We are 6-ethynyl-4,4-dimethyl-2,3-dihydrothiochromene CAS:118292-06-1 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: 6-ethynyl-4,4-dimethyl-2,3-dihydrothiochromene
CAS.NO:118292-06-1
Synonyms:
4,4-dimethyl-6-ethylyl-thiochroman
2H-1-Benzothiopyran,6-ethynyl-3,4-dihydro-4,4-dimethyl
(4,4-dimethylthiochroman-6-yl)acetylene
6-Ethynyl-4,4-dimethylthiochroman
4,4-dimethyl-6-ethynyl-thiochromane
(4,4-dimethyl-thiochroman-6-yl)ethyne
4,4-DIMETHYL-6-ETHYNYLTHIOCHROMAN

Molecular Formula:C13H14S
Molecular Weight:202.31500

Physical and Chemical Properties:
Density: 1.09
Boiling point: 299ºC
Melting point: 69-72ºC
Flash point: 128ºC
Refractive index: 1.597

Specification:
Appearance: White  powder
Purity:≥99%
Moisture Content: 0.1%
Impurity: 0.1%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Tazarotene CAS:118292-40-3

6-ethynyl-4,4-dimethyl-2,3-dihydrothiochromene


Related News: In August, the Company announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 10,370,452 covering compositions and uses of effector T cells expressing a CAR, where such T cells are derived from a pluripotent stem cell, including an iPSC.2-Brom-xanthen-9-on Due to the cyclic nature of the upstream chemical products of the API, it is expected that the impact of price fluctuations of raw materials on the performance of API companies is unavoidable, but companies with thick product lines and the ability to produce intermediates are expected to minimize the upstream price impact.2'-O-methylguanosine Optimize the reaction and improve the production process to reduce the production cost. At the same time, strengthen the determination and analysis of impurities to improve product quality.Methyl 5-fluoro-2-methyl-3-nitrobenzoate CAS:697739-03-0 Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).Additional results from the trial with data on another goal of extending survival is expected in 2020, AstraZeneca said.

Related Products
Product Name
1-dimethoxyphosphoryl-3-phenoxypropan-2-one View Details
2-oxo-6-(trifluoromethyl)-1H-pyridine-3-carboxylic acid View Details
2-Formylbenzeneboronic acid View Details
(6-phenylnaphthalen-2-yl)boronic acid manufacturer 3-Iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine manufacturer 1,10-Dibromodecane manufacturer 5,6-Dimethoxy-2-(4-Piperidinylmethyl)-1-Indanone Hydrochloride manufacturer 2-chloro-4-(naphthalen-2-yl)-6-phenyl-1,3,5-triazine manufacturer